City Holding Co. Lowers Position in Pfizer Inc. (NYSE:PFE)

City Holding Co. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 3.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,674 shares of the biopharmaceutical company’s stock after selling 1,130 shares during the quarter. City Holding Co.’s holdings in Pfizer were worth $1,725,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in PFE. Harbor Investment Advisory LLC increased its stake in Pfizer by 3.6% in the fourth quarter. Harbor Investment Advisory LLC now owns 23,977 shares of the biopharmaceutical company’s stock valued at $1,229,000 after acquiring an additional 825 shares during the last quarter. Saxon Interests Inc. boosted its holdings in shares of Pfizer by 12.9% in the 3rd quarter. Saxon Interests Inc. now owns 8,309 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 951 shares in the last quarter. Platte River Wealth Advisors LLC increased its position in shares of Pfizer by 62.8% during the 3rd quarter. Platte River Wealth Advisors LLC now owns 12,717 shares of the biopharmaceutical company’s stock valued at $556,000 after purchasing an additional 4,905 shares during the last quarter. Accuvest Global Advisors raised its holdings in shares of Pfizer by 16.6% during the 3rd quarter. Accuvest Global Advisors now owns 12,994 shares of the biopharmaceutical company’s stock valued at $569,000 after buying an additional 1,848 shares in the last quarter. Finally, Secure Asset Management LLC lifted its position in Pfizer by 3.5% in the 4th quarter. Secure Asset Management LLC now owns 15,835 shares of the biopharmaceutical company’s stock worth $811,000 after buying an additional 537 shares during the last quarter. 67.62% of the stock is currently owned by institutional investors.

Get Pfizer alerts:

Analysts Set New Price Targets

Several research firms have commented on PFE. The Goldman Sachs Group raised shares of Pfizer from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $47.00 to $60.00 in a research note on Tuesday, December 13th. BMO Capital Markets lowered their price target on shares of Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a research note on Wednesday, February 1st. Credit Suisse Group reduced their price objective on Pfizer from $54.00 to $50.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 1st. StockNews.com initiated coverage on Pfizer in a research note on Thursday, March 16th. They issued a “buy” rating for the company. Finally, JPMorgan Chase & Co. set a $45.00 price target on Pfizer in a research report on Monday, February 27th. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $49.93.

Pfizer Price Performance

Shares of Pfizer stock opened at $41.50 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.22 and a debt-to-equity ratio of 0.34. The business has a 50 day moving average of $41.66 and a 200 day moving average of $45.47. The company has a market cap of $234.24 billion, a PE ratio of 7.57, a P/E/G ratio of 1.40 and a beta of 0.64. Pfizer Inc. has a 52 week low of $39.23 and a 52 week high of $56.32.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The company had revenue of $24.30 billion for the quarter, compared to analysts’ expectations of $24.40 billion. During the same quarter in the previous year, the company earned $1.08 earnings per share. Pfizer’s quarterly revenue was up 1.9% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer Inc. will post 3.3 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder Pfizer Inc bought 1,811,594 shares of the stock in a transaction dated Friday, March 17th. The stock was bought at an average price of $2.76 per share, for a total transaction of $4,999,999.44. Following the purchase, the insider now directly owns 5,952,263 shares in the company, valued at approximately $16,428,245.88. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.05% of the company’s stock.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Further Reading

• Get a free copy of the StockNews.com research report on Pfizer (PFE)
• MarketBeat Week in Review – 4/3 – 4/7
• Costco Sales Disappoint, Markets Are Missing This Upside Driver
• First Republic Bank Is A Speculative Play, Here’s Why
• The WD-40 Company Bottoms With Reversal In Sight 
• 3 Low-Cost Stock ETFs That Are Crushing It This Year

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.